Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

Rhea-AI Summary

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, has scheduled its first quarter 2025 financial results announcement for May 5, 2025, before market opening. The company will host a conference call at 8:30 a.m. ET (5:30 a.m. PT) featuring President and CEO John Aballi and CFO Jeff Black.

Participants can join via phone at 201-389-0918 (U.S.) or +1-877-407-0890 (international), or through webcast available on the company's investor relations website. A replay will be accessible until May 19, 2025, through phone (201-612-7415 U.S., +1-877-660-6853 international, passcode 13753132) or webcast.

CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT).

Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

A replay of the conference call will be available until Monday, May 19, 2025. Interested parties may access the replay by dialing 201-612-7415 (U.S.) or +1-877-660-6853 (international) using passcode 13753132. Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately one hour after the call concludes.

About Exagen Inc.

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE^® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.

For more information, visit Exagen.com or follow @ExagenInc on X.

Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525

FAQ

When will Exagen (XGN) release its Q1 2025 earnings?

Exagen will release its Q1 2025 financial results on Monday, May 5, 2025, before the market opens.

How can investors join Exagen's Q1 2025 earnings call?

Investors can join via phone (201-389-0918 U.S., +1-877-407-0890 international) or through webcast at investors.exagen.com at 8:30 a.m. ET.

Until when will Exagen's Q1 2025 earnings call replay be available?

The earnings call replay will be available until Monday, May 19, 2025, via phone or webcast.

What is the passcode for Exagen's Q1 2025 earnings call replay?

The passcode for accessing the earnings call replay is 13753132.